Featuring perspectives from Drs Mansoor Raza Mirza, Amit M Oza and Richard T Penson, moderated by Dr Joyce F Liu. Published April 13, 2023. (Webinar Video Proceedings)
TARGET AUDIENCE
This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of ovarian cancer.
LEARNING OBJECTIVES
ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Research To Practice designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
HOW TO USE THIS CME ACTIVITY
This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/SGO23Ovarian/Video/CME.
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
Mansoor Raza Mirza, MD
Chief Oncologist
Copenhagen University Hospital
Medical Director
Nordic Society of Gynaecological Oncology – Clinical Trial Unit
Vice President, European Society of Gynaecological Oncology
Copenhagen, Denmark
Advisory Committee: Boehringer Ingelheim Pharmaceuticals Inc, Clovis Oncology, GSK, Karyopharm Therapeutics, Merck, Roche Laboratories Inc, Zai Lab; Consulting Agreements: Boehringer Ingelheim Pharmaceuticals Inc, Clovis Oncology, GSK, Karyopharm Therapeutics, Merck, Novartis, Roche Laboratories Inc, Zai Lab; Nonrelevant Financial Relationship: Chairman 2020-2022, European Network of Gynaecological Trial Groups.
Amit M Oza, MD
Bergsagel Chair in Medical Oncology
Professor of Medicine
University of Toronto
Head, Division of Medical Oncology and Hematology
Director, Clinical Cancer Research and BRAS Drug Development Program
Princess Margaret Cancer Centre
UHN and Mount Sinai Health System
Toronto, Ontario, Canada
No relevant conflicts of interest to disclose.
Richard T Penson, MD, MRCP
Associate Professor of Medicine
Harvard Medical School
Clinical Director, Medical Gynecologic Oncology
Massachusetts General Hospital
Boston, Massachusetts
Advisory Committee: AstraZeneca Pharmaceuticals LP, Eisai Inc, GSK, ImmunoGen Inc, Merck, Mersana Therapeutics Inc, Novocure Inc, Roche Laboratories Inc, Sutro Biopharma, VBL Therapeutics; Contracted Research: Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Eisai Inc, Genentech, a member of the Roche Group, Regeneron Pharmaceuticals Inc, Sanofi, Tesaro, A GSK Company, VBL Therapeutics; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, Roche Laboratories Inc; Nonrelevant Financial Relationship: BMJ Publishing Group Ltd, Elsevier, UptoDate, Wiley-Blackwell, Wolters Kluwer Health.
MODERATOR
Joyce F Liu, MD, MPH
Associate Chief and Director of Clinical Research
Division of Gynecologic Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts
Advisory Committee: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, GSK, Regeneron Pharmaceuticals Inc; Consulting Agreement: Bristol-Myers Squibb Company; Trial Support (to Institution for Study Conduct): 2X Oncology Inc, Aravive Inc, Arch Oncology, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Clovis Oncology, CytomX Therapeutics, GSK, Impact Therapeutics, Regeneron Pharmaceuticals Inc, Vigeo Therapeutics, Zentalis Pharmaceuticals.
RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, GSK, ImmunoGen Inc, Merck, Mersana Therapeutics Inc, and Novocure Inc.
Release date: April 2023
Expiration date: April 2024
After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.
(WIFI is recommended for best performance):